Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

Estimated cumulative complete clearance by Day 84 reached 60.1% with YCANTH versus 19.9% with vehicle.

Rhea-AI Summary

Verrica Pharmaceuticals (VRCA) will present a new pooled analysis of YCANTH Phase 3 trials showing faster complete clearance of molluscum contagiosum. The post-hoc analysis of CAMP-1 and CAMP-2 found an approximately 4-fold faster rate of complete clearance versus vehicle, regardless of disease duration. Estimated cumulative complete clearance by Day 84 was 60.1% versus 19.9%.

The YCANTH poster will appear at Fall Clinical on October 8–11, 2026, and PeDRA on October 15–17, 2026. Fall Clinical will also feature an encore exploratory Phase 2 analysis of VP-315 examining potential effects on untreated basal cell carcinoma tumors after injections into separate target tumors.

Positive

• Minor pointYCANTH achieved complete clearance at an approximately 4-fold faster rate than vehicle, regardless of disease duration.
• Minor pointEstimated cumulative complete clearance by Day 84 was 60.1% with YCANTH versus 19.9% with vehicle.

Negative

• Minor pointYCANTH findings come from a post-hoc pooled analysis of two completed Phase 3 trials.
• Minor point. Forward-looking: it has not happened yet and may not happen.VP-315 effects on untreated tumors remain potential, based on an exploratory Phase 2 analysis.

Key Figures

Hazard ratio: HR=4.06 (95% CI, 2.94–5.74) Day 84 complete clearance: 60.1% with VP-102 vs. 19.9% with vehicle Sensitivity analysis estimates: 4.05–4.19

Hazard ratio

HR=4.06 (95% CI, 2.94–5.74)

VP-102 versus vehicle for time to complete clearance

Day 84 complete clearance

60.1% with VP-102 vs. 19.9% with vehicle

Kaplan-Meier cumulative complete clearance

Sensitivity analysis estimates

4.05–4.19

Treatment-effect estimates across sensitivity analyses

Historical Context

1 past event · Latest: Sep 10

1 event

1. Sep 10

   Phase 3 data presentation

   24h Move

   -2.2%

   Earlier pooled analysis reported Day 84 clearance by disease-duration subgroup, contextualizing this pooled clearance analysis.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

post-hoc pooled analysis, kaplan-meier, abscopal-like effects, intratumoral, +1 more

5 terms

post-hoc pooled analysis technical

"results from a post-hoc pooled analysis of two completed Phase 3 trials"

An analysis that combines (pools) participant-level or summary data from two or more separate studies or clinical trial arms after those studies are completed and then examines outcomes or subgroups that were not specified in the original study plans. It is performed retrospectively to look for patterns or associations across the combined dataset; because the pooling and the specific comparisons were not pre-specified, results are considered exploratory and can be affected by differences in trial design, patient populations, endpoint definitions, and multiple-testing bias.

kaplan-meier medical

"Kaplan-Meier cumulative complete clearance by Day 84"

A Kaplan-Meier estimate is a statistical curve that shows how long it takes for a particular event—such as recovery, relapse, or death—to occur in a group over time, with the curve stepping down as events happen. Investors use these curves to assess the duration and timing of a treatment's or risk's effects—like watching how many light bulbs remain working week by week—because the timing and likelihood of outcomes influence clinical decisions, regulatory approval, and revenue prospects.

abscopal-like effects medical

"describing an exploratory analysis of potential abscopal-like effects"

A phenomenon in oncology where a treatment applied to a local tumor (most classically radiation) produces tumor shrinkage or disease control at distant, untreated sites; the effect is believed to be mediated by activation of the immune system against cancer cells and can also be seen when other local therapies are combined with systemic immunomodulation. It is uncommon, not fully predictable, and described as “abscopal-like” when the remote responses resemble the classic abscopal effect but arise from different local treatments or combination approaches.

intratumoral medical

"following intratumoral treatment with VP-315 of separate target lesions"

"Intratumoral" describes something that occurs or exists within a tumor, which is an abnormal growth of tissue. For investors, understanding intratumoral is important because it relates to medical treatments or research aimed at targeting the tumor directly, potentially leading to more effective therapies. Think of it as focusing treatment straight into the problem area, much like fixing a leak by working directly on the pipe itself.

oncolytic peptide immunotherapy medical

"the Company's investigational oncolytic peptide immunotherapy"

A cancer treatment approach that uses short chains of amino acids (peptides) designed to kill tumor cells directly and to stimulate the patient’s immune system against the cancer. These peptides act by disrupting cancer-cell membranes or triggering cell death, which can release tumor proteins that help prime an immune response; they may be delivered locally or systemically and are often developed to be used alongside other immunotherapies. The phrase describes a class of investigational therapies and not a specific drug or regulatory designation; safety, dosing, and approval depend on clinical-trial and regulatory outcomes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –

WEST CHESTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will present posters on a new analysis of Phase 3 trials of YCANTH® (VP-102) and an encore presentation of data from a Phase 2 trial of VP-315. Verrica will present at the Fall Clinical Dermatology Conference (October 8–11, Wynn Las Vegas, Las Vegas, NV) and at the 2026 PeDRA Annual Conference (October 15–17, Alexandria, VA).

"We remain highly encouraged by the continued generation of clinical evidence supporting our dermatology portfolio," said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. "These new pooled data from the CAMP-1 and CAMP-2 Phase 3 trials reinforce VP-102’s profile as the new standard of care for molluscum contagiosum, showing that patients may achieve complete clearance of their molluscum lesions approximately four times faster than with vehicle, regardless of how long patients have had the disease. In addition, three times as many patients treated with YCANTH achieved complete clearance versus vehicle at each time point measured during the two trials, which reflects the consistent and durable treatment effects of YCANTH. We believe this new analysis provides physicians further confidence to treat patients with YCANTH as soon as a diagnosis is made, rather than defaulting to a ‘watch and wait’ approach typically employed by healthcare professionals before an FDA-approved option existed for patients."

"We continue to analyze the YCANTH data to help us better understand its ability to reduce the impact of disease upon patients, and accelerate their return to normal activities," added Noah L. Rosenberg, M.D., Chief Medical Officer of Verrica. "This data, demonstrating more rapid complete clearance with YCANTH, independent of disease duration, gives clinicians a clear, data-driven rationale for early intervention rather than watchful waiting."

About the Posters:

VP-102 Achieved Complete Clearance Approximately 4 Times Faster Than Vehicle, Regardless of Disease Duration

The Company will present results from a post-hoc pooled analysis of two completed Phase 3 trials of YCANTH for the treatment of molluscum contagiosum (molluscum), evaluating time to first complete clearance and the impact of disease duration on treatment response.

Key new findings include:

• Subjects treated with VP-102 achieved complete clearance at an approximately 4-fold faster rate than vehicle (HR=4.06; 95% CI, 2.94–5.74), with treatment-effect estimates ranging from 4.05 to 4.19 across sensitivity analyses.
• Kaplan-Meier cumulative complete clearance by Day 84 was 60.1% with VP-102 versus 19.9% with vehicle.

Potential Abscopal Effect of VP-315 in Untreated Basal Cell Carcinoma Tumors

Verrica will present an encore poster, previously presented at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, describing an exploratory analysis of potential abscopal-like effects of VP-315, the Company's investigational oncolytic peptide immunotherapy, in patients with basal cell carcinoma (BCC). The analysis examined untreated, non-target lesions (NTLs) in subjects from Part 2 of a Phase 2 multicenter study following intratumoral treatment with VP-315 of separate target lesions.

Presentation Details

2026 Fall Clinical Dermatology Conference | October 8–11, 2026 | Wynn Las Vegas, Las Vegas, NV

• Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
  Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
  Time of Poster Session:
  • Friday, October 9^th, 7:00 am - 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
  • Saturday, October 10^th, 7:30 am - 12:30 pm PDT (Exhibits and Poster Gallery Open)
  • Sunday, October 11^th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)
    

• Poster: VP-315 Demonstrates a Potential Abscopal Effect in Untreated Non-Target Basal Cell Carcinoma (BCC) Tumors (Encore)
  Convention/Meeting Space: Cristal Ballrooms 1, 3, 5, 7
  Time of Poster Session:
  • Friday, October 9^th, 7:00 am - 6:00 pm PDT with Scientific Poster Review session from 4:00 pm -5:00 pm PDT
  • Saturday, October 10^th, 7:30 am - 12:30 pm PDT (Exhibits and Poster Gallery Open)
  • Sunday, October 11^th, 7:00 am – 1:00 pm PDT (Poster Gallery Open)
    

2026 PeDRA Annual Conference | October 15–17, 2026 | Alexandria, VA

• Poster: VP-102 Demonstrates More Rapid Complete Clearance of Molluscum Contagiosum Regardless of Disease Duration: A Pooled Analysis of Two Phase 3 Trials
  Convention/Meeting Space: Hilton Alexandria Mark Center
  Time of Poster Session: October 15-17, 2026 (Poster Reception Thursday, October 15^th at 5:00 pm EDT)

About YCANTH® (VP-102)

YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH is the first and only healthcare professional-administered product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information.

YCANTH is now approved for the treatment of molluscum contagiosum in Japan based upon an additional Phase 3 trial of approximately 300 patients. YCANTH is being studied in a global Phase 3 program in the US and Japan for use in the treatment of common warts.

About VP-315 (ruxotemitide)

VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in "host defense peptides" – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials.

About Verrica Pharmaceuticals Inc.

Verrica is a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers. Verrica's product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma ASA to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," and similar expressions, and are based on Verrica's current beliefs and expectations. These forward-looking statements include statements about the clinical development and potential benefits of Verrica's product candidates, including YCANTH (VP-102) and VP-315, and the data described in this press release. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions and other risks and uncertainties that are described in Verrica's Annual Report on Form 10-K for the year ended December 31, 2025, Verrica's Quarterly Reports on Form 10-Q and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

John Kirby
Interim Chief Financial Officer
jkirby@verrica.com

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Verrica's new YCANTH analysis show about molluscum clearance?

YCANTH achieved complete clearance at an approximately 4-fold faster rate than vehicle, regardless of disease duration. Estimated cumulative complete clearance by Day 84 was 60.1% with YCANTH versus 19.9% with vehicle in the pooled analysis of two completed Phase 3 trials.

How consistent was the YCANTH treatment effect across Verrica's sensitivity analyses?

Treatment-effect estimates ranged from 4.05 to 4.19 across sensitivity analyses. The main hazard ratio, a measure comparing the rate of first complete clearance, was 4.06, with a 95% confidence interval of 2.94–5.74.